# US 2002/0001625 A1 · Growth-promoting agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0001625 A1
- Document ID: US20020001625A1
- Status: Published application
- Kind: A1
- Application number: 09/912,040
- Filed: 2001-07-24
- Published: 2002-01-03
- Earliest claimed: 1990-07-13
- Assignees: GroPep Limited located
- Inventors: Francis John Ballard; Geoffrey Leonard Francis; Geoffrey Owen Regester; Leanna Christine Read; David Andrew Belford
- Web page: https://patentgrep.com/patent/US20020001625A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61K 35/20: Milk; Whey; Colostrum
- A61K 38/1709: {from mammals}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to pharmaceutical or veterinary compositions for the treatment of surface wounds; pharmaceutical or veterinary compositions for the treatment of gastrointestinal injuries, diseases or ulcers; methods of treating surface wounds in animals, including humans; and methods for the treatment of gastrointestinal injuries, diseases or ulcers which compositions and methods include compositions of milk product extracts including growth factors with basic to approximately neutral isoelectric points.

## Claims

### Claim 1

A pharmaceutical or veterinary composition for the treatment of surface wounds which composition comprises:
(a) a milk product extract that contains a mixture of cell growth factors with basic to approximately neutral isoelectric points obtained from a milk product of an ungulate mammal by first subjecting that product to a cation exchange matrix under conditions whereby casein, alpha lactalbumin, and beta lactoglobulin present in the milk product are not absorbed to the matrix, after which the absorbed growth factor mixture is eluted and then concentrated; and
(b) a pharmaceutically or veterinarily acceptable diluent, carrier or excipient therefor.

### Claim 2 (depends on 1)

A composition according to claim 1 further including an effective amount of at least one active ingredient selected from antibiotics, antiseptics, other growth promotants, anaesthetics, and mixtures thereof.

### Claim 3 (depends on 1)

A composition according to claim 1 wherein the cell growth factors have isoelectric points between about 6.0 and about 10.5.

### Claim 4

A pharmaceutical or veterinary composition for the treatment of gastrointestinal injuries, diseases or ulcers which composition comprises:
(a) a milk product extract that contains a mixture of cell growth factors with basic to aproximately neutral isoelectric points that are obtained from a milk product of an ungulate mammal by first subjecting that product to a cation exchange matrix under conditions whereby casein, alpha lactalbumin, and beta lactoglobulin present in the milk product are not absorbed to the matrix, after which the absorbed growth factor mixture is eluted and then concentrated; and
(b) a pharmaceutically or veterinarily acceptable diluent, carrier or excipient therefor.

### Claim 5 (depends on 4)

A composition according to claim 4 further including an effective amount of at least one active ingredient selected from antibiotics, antiseptics, other growth promotants, anaesthetics, and mixtures thereof.

### Claim 6 (depends on 4)

A composition according to claim 4 wherein the cell growth factors have isoelectric points between about 6.0 and about 10.5.

### Claim 7

A method of treating surface wounds in animals, including humans, which method comprises administering to a subject to be treated an effective amount of a pharmaceutical or veterinary composition, which composition comprises:
(a) a milk product extract that contains a mixture of cell growth factors with basic to approximately neutral isoelectric points that are obtained from a milk product of an ungulate mammal by first subjecting that product to a cation exchange matrix under conditions whereby casein, alpha lactalbumin, and beta lactoglobulin present in the milk product are not absorbed to the matrix, after which the absorbed growth factor mixture is eluted and then concentrated; and
(b) a pharmaceutically or veterinarily acceptable diluent, carrier or excipient therefor.

### Claim 8 (depends on 7)

The method according to claim 7 wherein the surface wounds are selected from the group consisting of ulcers, conditions that results from surgery, therapeutically induced wounds, wounds associated with disorders of the central nervous system, any exfoliative disease of the skin, wounds associated with local or systemic infection, congenital wounds, pathological wounds, traumatic and accidental wounds, and burns.

### Claim 9 (depends on 7)

A method according to claim 7 wherein the cell growth factors have isoelectric points between about 6.0 and about 10.5.

### Claim 10

A method for the treatment of gastrointestinal injuries, diseases or ulcers, which method comprises administering to a subject to be treated an effective amount of a pharmaceutical or veterinary composition, which composition comprises:
(a) a milk product extract that contains a mixture of cell growth factors with basic to approximately neutral isoelectric points that are obtained from a milk product of an ungulate mammal by first subjecting that product to a cation exchange matrix under conditions whereby casein, alpha lactalbumin, and beta lactoglobulin present in the milk product are not absorbed to the matrix, after which the absorbed growth factor mixture is eluted and then concentrated; and
(b) a pharmaceutically or veterinarily acceptable diluent, carrier or excipient therefor.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the gastrointestinal injuries, diseases or ulcers are selected from the group consisting of dental and oral wounds, peptic ulcers, inflammatory bowel diseases, ulcers associated with stress conditions, damage caused by radiotherapy and/or chemotherapy, inadequate gut function or damage associated with prematurity, diarrheal conditions, damage caused by food intolerance, cancer of the gastrointestinal tract, surgically induced damage, damage caused by esophageal reflux, conditions associated with loss of gut barrier function, congenital conditions resulting in inadequate gastrointestinal function or damage, and autoimmune diseases that affect the gut.

### Claim 12 (depends on 10)

A method according to claim 10 wherein the cell growth factors have isoelectric points between about 6.0 and about 10.5.
